Clinical trials located in

Rendsburg

Rendsburg city is located in Germany. Currently, 6 clinical trials are being conducted in this city.

Rendsburg, located in northern Germany, is a city rich in history and culture. Founded in 1199, it is renowned for its High Bridge, a remarkable steel structure that spans the Kiel Canal, the busiest artificial waterway in the world. This engineering marvel, coupled with the transporter bridge beneath it, showcases the city’s unique blend of historical and modern infrastructure. Rendsburg also hosts the annual NordArt, one of Europe’s largest contemporary art exhibitions, highlighting its vibrant cultural scene. The city’s strategic position and historical significance, including its role in the Thirty Years’ War, add layers to its intriguing character.

  • CT-EU-00057647

    Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    • Secukinumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing the efficacy and safety of a new drug for knee osteoarthritis pain

    This study is testing a new drug called GSK3858279 for adults suffering from moderate to severe knee joint pain. The main goal is to determine what is the best, safe and effective dose to administer. Participants will be asked to rate their daily knee pain on a scale of 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. This weekly average score will help us understand better. A questionnaire called WOMAC will also be used to understand the overall health and function of the knees and joints, especially in terms of pain, stiffness and functionality. They will also be rated on a scale of 0 to 10. Any side effects, serious side effects, and specific side effects associated with the drug and medical conditions will also be considered. Finally, the science behind the drug’s effects on pain will be analyzed using several measures.

    • GSK3858279- new potential medication for chronic pain associated with osteoarthritis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.